After reaching an important support level, MARKER THERAPEUTICS, INC. (MRKR) could be a good stock pick from a technical perspective. MRKR recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.Considered an important signifier for a bullish breakout, a golden cross is a technical chart pattern that's formed when a stock's short-term moving average breaks above a longer-term moving average; the most common crossover involve ...

After a sluggish first half, the drug and biotech sector has staged a recovery over the past two to three months. This rebound was supported by major drugmakers signing drug pricing agreements with the Trump administration, which eased concerns around potential tariff-related impacts and removed a key policy overhang. Renewed momentum in mergers and acquisitions (M&A) has further strengthened investor sentiment across the industry.At the same time, innovation remains a key growth driver, with high-interest ...

Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study Study highlights correlation between the clinical benefit and the expansion and persistence of Multi-Antigen Targeted T cells HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Targeted T cel ...

Core Insights - Several small-cap biotech and healthcare companies experienced notable gains in after-hours trading, driven by recent corporate updates and clinical milestones Company Updates - Inspira Technologies Oxy B.H.N. Ltd. (IINN) rose 5.88% to $1.08 following a recent definitive agreement for a registered direct offering of its ordinary shares and a Standby Equity Purchase Agreement with YA II PN, Ltd. [2] - Galectin Therapeutics Inc. (GALT) increased by 1.79% to close at $6.27, despite no new corporate developments reported [3] - MediciNova, Inc. (MNOV) advanced 4.83% to $1.52 after successfully completing patient enrollment in its Phase 2 OXTOX study, evaluating MN-166 for chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer patients [4] - Marker Therapeutics, Inc. (MRKR) gained 5.56% to $1.33 without any new company-specific announcements [5] - Sharps Technology, Inc. (STSS) climbed nearly 4% to $2.09, also without fresh updates [6] - DiaMedica Therapeutics Inc. (DMAC) rose 2.89% to $8.55 after a productive pre-IND meeting with the FDA regarding its planned study of DM199 in preeclampsia [6] - Corbus Pharmaceuticals Holdings, Inc. (CRBP) edged higher by 1.36% to $8.21, following the completion of its Phase 1a study of CRB-913 and initiation of the Phase 1b CANYON-1 trial [7] - ProMIS Neurosciences, Inc. (PMN) added 0.83% to $8.49, recovering slightly after a decline earlier in the day, with the completion of enrollment of 144 patients in its PRECISE-AD Phase 1b clinical trial for Alzheimer's disease [8]

Core Points - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1] Summary by Categories Technical Requirements - Users are advised to enable Javascript and cookies in their browsers to ensure proper functionality [1] - The presence of ad-blockers can lead to blocked access, necessitating their disabling for content access [1]

Clinical Development - MT-601 achieved a 66% objective response rate and a 50% complete response rate in relapsed Non-Hodgkin lymphoma patients during the APOLLO study[4] - The first patient was treated in the Off-the-Shelf (OTS) program investigating MAR-T cells for Acute Myeloid Leukemia or Myelodysplastic Syndrome[4] - The company anticipates additional clinical data from the APOLLO study in the first half of 2026[8] - Marker was awarded $2.0 million from the NIH and $9.5 million from CPRIT to support the development of MT-601 in metastatic pancreatic cancer[8] Financial Performance - The net loss for Q3 2025 was $2.0 million, an improvement from a net loss of $2.3 million in Q3 2024[11] - For the nine months ended September 30, 2025, the net loss was $10,460,410, compared to a net loss of $6,893,691 for the same period in 2024, indicating an increase in losses of approximately 51%[21] - Net cash used in operating activities for the nine months ended September 30, 2025, was $10,113,975, up from $6,207,189 in 2024, reflecting a 63% increase in cash outflow[21] - Cash, cash equivalents, and restricted cash at the end of the period were $18,942,953, a decrease from $19,192,440 at the beginning of the period[21] - The net decrease in cash, cash equivalents, and restricted cash for the nine months ended September 30, 2025, was $249,487, compared to a much larger decrease of $6,111,786 in 2024[21] Expenses - Research and development expenses for Q3 2025 were $2.3 million, down from $3.5 million in Q3 2024[10] - General and administrative expenses for Q3 2025 were $1 million, compared to $0.9 million in Q3 2024[10] - The company reported stock-based compensation of $426,409 for the nine months ended September 30, 2025, compared to $195,320 in 2024, representing a 118% increase[21] Cash Management - The company raised approximately $10 million through its ATM facility, extending its cash runway into 2026[4] - As of September 30, 2025, Marker had cash and cash equivalents of $17.6 million and restricted cash of $1.4 million, expected to fund operations through Q3 2026[9] - The company raised $9,863,883 from the issuance of common stock during the nine months ended September 30, 2025, compared to $36,902 in 2024, showing a significant increase in financing activities[21] Other Financial Metrics - Deferred revenue increased to $1,352,975 for the nine months ended September 30, 2025, indicating potential future revenue recognition[21] - The company experienced a significant change in accounts payable and accrued expenses, which decreased by $901,449 from the previous year[21] - Proceeds from the exercise of warrants and stock options were $605 for the nine months ended September 30, 2025, down from $58,501 in 2024, indicating a decline in stock option activity[21] - Other receivables increased to $681,550 for the nine months ended September 30, 2025, compared to $283,405 in 2024, reflecting improved collection or new receivables[21] Manufacturing Collaboration - Marker entered a cGMP manufacturing collaboration with Cellipont Bioservices to scale up production of MT-601[2]

Core Insights - Marker Therapeutics reported promising results from the Phase 1 APOLLO study, showing a 66% objective response rate and 50% complete response rate in relapsed Non-Hodgkin lymphoma patients, indicating the potential of MT-601 as a treatment option for patients with limited therapy options [2][5] - The company has initiated its Off-the-Shelf program, treating the first patient in the RAPID study, which focuses on MAR-T cells for Acute Myeloid Leukemia and Myelodysplastic Syndrome [2][12] - A strategic manufacturing collaboration with Cellipont Bioservices has been established to enhance the production capabilities of MT-601, supporting clinical supply and future pivotal trials [2][12] Clinical Updates - The APOLLO study demonstrated durable responses, with five patients maintaining responses for at least six months, and three for over twelve months [5] - No dose-limiting toxicities or immune effector cell-associated neurotoxicity were observed, highlighting a favorable safety profile for MT-601 [5] - The ongoing dose expansion cohort is evaluating MT-601 at the highest dose level in patients with Diffuse Large B Cell Lymphoma who have relapsed or are ineligible for CAR-T therapy [5] Financial Highlights - As of September 30, 2025, Marker Therapeutics had cash and cash equivalents of $17.6 million and restricted cash of $1.4 million, which is expected to fund operations through the third quarter of 2026 [8] - Research and development expenses for Q3 2025 were $2.3 million, a decrease from $3.5 million in Q3 2024, while general and administrative expenses increased slightly to $1 million from $0.9 million [9] - The company reported a net loss of $2.0 million for Q3 2025, compared to a net loss of $2.3 million in the same quarter of the previous year [10] Corporate Developments - Marker Therapeutics raised approximately $10 million through its ATM facility, extending its cash runway into 2026 [2][12] - The company has received non-dilutive funding from NIH and CPRIT to support the development of MT-601 in metastatic pancreatic cancer, with a clinical program launch anticipated in the first half of 2026 [5][12] - The appointment of Kathryn Penkus Corzo to the Board of Directors was announced, effective November 1, 2025 [12]

Financial Performance - Total revenues for the three months ended September 30, 2025, were $1,233,000, a decrease of 36% compared to $1,926,000 in the same period of 2024[122]. - Total revenues for the nine months ended September 30, 2025 were $2.4 million, a decrease of 44% from $4.3 million in 2024[139]. - The net loss for the nine months ended September 30, 2025 was $10.5 million, an increase of 52% from a net loss of $6.9 million in 2024[139]. Research and Development - Research and development expenses decreased by 32% to $2,346,000 for the three months ended September 30, 2025, compared to $3,471,000 in 2024[122]. - Research and development expenses increased by 15% to $9.7 million for the nine months ended September 30, 2025, compared to $8.4 million in 2024[152]. - The company has a pipeline that includes two product candidates for three clinical indications as part of the MAR-T cell program[105]. Clinical Trials and Studies - Eight out of 12 Non-Hodgkin Lymphoma (NHL) patients achieved objective responses (66%) in the Phase 1 APOLLO study, with 50% demonstrating complete response (CR)[111]. - The company reported no treatment-related side effects in the APOLLO study, indicating a favorable safety profile for the MAR-T cell therapy[110]. - The company entered into a Statement of Work with Cellipont Bioservices for the manufacturing of MT-601, supporting the scale-up for the APOLLO study[114]. Grants and Funding - The company received a $2.0 million grant from the NIH SBIR program in August 2024 to support MT-601 for pancreatic cancer, recognizing approximately $0.2 million in revenue for the nine months ended September 30, 2025[129]. - An additional $9.5 million grant from CPRIT was awarded in December 2024 for MT-601 in metastatic pancreatic cancer, with $1.4 million recorded as restricted cash and deferred revenue as of September 30, 2025[130]. - The Company received a total of $2.0 million in grants from the NIH SBIR program to support the development of MT-401 for AML patients, with $1.5 million received to date[170]. Operating Expenses - Operating expenses for the three months ended September 30, 2025 were $3.4 million, a decrease of 21% from $4.3 million in the same period in 2024[131]. - Operating expenses for the three and nine months ended September 30, 2025, were $3.4 million and $13.4 million, respectively, compared to $4.3 million and $11.6 million in the prior year periods[177]. - General and administrative expenses increased by 20% to $1.0 million for the three months ended September 30, 2025, primarily due to headcount-related expenses[135]. Stock and Capital - The company sold 1,624,075 shares of common stock for net proceeds of $4.5 million at an average price of $2.87 per share between July 17 and 21, 2025[119]. - An additional 3,734,217 shares were sold for net proceeds of $5.4 million at an average price of $1.48 per share on August 26, 2025[176]. - The Company plans to continue funding operations through equity and/or debt financing, which may dilute existing stockholders' interests[179]. Future Outlook - The company anticipates continued net losses as it invests in research and development activities, including clinical development of MAR-T cell product candidates[138]. - The company expects to fund its operating expenses through the third quarter of 2026, assuming no additional grant funds are received[159]. - High inflation and economic recession concerns may negatively affect the Company's liquidity and ability to access capital[180].

Core Viewpoint - Marker Therapeutics, Inc. has appointed Kathryn Penkus Corzo to its Board of Directors, effective November 1, 2025, to strengthen its leadership as it advances its clinical programs, particularly the APOLLO program for CAR-relapsed Diffuse Large B Cell Lymphoma (DLBCL) [1][4]. Company Overview - Marker Therapeutics is a clinical-stage immuno-oncology company based in Houston, TX, focusing on next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [6]. - The company was founded at Baylor College of Medicine and has conducted clinical trials involving over 200 patients, demonstrating that its autologous and allogeneic MAR-T cell products are well tolerated and show durable clinical responses [6]. Leadership Appointment - Kathryn Penkus Corzo brings over 30 years of experience in biopharma, including roles in R&D, clinical trials, regulatory approvals, and commercialization [2]. - Prior to joining Marker, she served as President and COO at bit.bio Ltd, where she expanded the company's product portfolio and established scalable operations [2]. - Corzo has held senior positions at Takeda Ventures, Sanofi Genzyme, Hoffmann-La Roche, Eli Lilly, and Syndax Pharmaceuticals, contributing to the development and launch of multiple global blockbuster cancer therapies [3]. Clinical Development Focus - Marker Therapeutics is committed to advancing its lead asset MT-601 and the APOLLO program, which targets CAR-relapsed DLBCL [4]. - The company emphasizes the potential of its Multi-Antigen Recognizing (MAR) T cell platform, which aims to address limitations of current treatments and improve clinical outcomes for patients with limited options [5]. MAR-T Cell Platform - The MAR-T cell platform is a novel, non-genetically modified cell therapy that selectively expands tumor-specific T cells capable of recognizing a broad range of tumor antigens [5]. - This approach allows recognition of hundreds of different epitopes within up to six tumor-specific antigens, potentially reducing the risk of tumor escape [5]. - Marker believes that its MAR-T cell products will be easier and less expensive to manufacture, with an improved safety profile compared to current engineered T cell therapies [5].

Core Insights - The Phase 1 APOLLO study of MT-601 in patients with relapsed B cell lymphomas has shown promising preliminary efficacy and a robust safety profile [1][2][3] Study Findings - MT-601 demonstrated an objective response rate (ORR) of 66% in Non-Hodgkin lymphoma (NHL) patients, with 50% achieving a complete response (CR) [2] - In Hodgkin lymphoma (HL), the ORR was 78%, with 11% achieving a CR [2] - Responses in NHL were durable, lasting from 3 to 24 months, with five patients remaining in remission for 6 months or longer [2] - The study reported no dose limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS) [1][2] Next Steps - The company has advanced to the dose expansion phase, evaluating MT-601 at the highest dose level (400x10 cells) in patients with Diffuse Large B Cell Lymphoma (DLBCL) [3] Presentation Details - Two posters will be presented at the 67th American Society of Hematology (ASH) Annual Meeting, detailing the safety and efficacy of MT-601 in relapsed or refractory Hodgkin and Non-Hodgkin lymphoma [4] About MT-601 - MT-601 is a multi-antigen recognizing (MAR) T cell therapy targeting six tumor antigens upregulated in lymphoma cells [5][6] - The therapy is being investigated for patients who have relapsed after or are not candidates for anti-CD19 CAR-T cell therapies [5][6] About APOLLO Trial - The APOLLO trial is a multicenter, open-label study designed to evaluate the safety and efficacy of MT-601 in participants with relapsed or refractory lymphoma [6] About MAR-T Cells - The MAR-T cell platform is a novel, non-genetically modified approach that selectively expands tumor-specific T cells capable of recognizing multiple tumor antigens [7] About Marker Therapeutics, Inc. - Marker Therapeutics is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [8]